IPS Securex is one of Singapore’s leading providers of security products and integrated security solutions to commercial entities and government bodies and agencies in Asia-Pacific.
Since 2000, it has been providing security products and integrated security solutions for various security requirements including checkpoint security, law enforcement and the protection and surveillance of buildings and critical infrastructure. It is a one-stop security solutions provider - from the supply of a broad range of security products, the design, installation, testing and commissioning of integrated security solutions, to the provision of maintenance support and leasing services to its customers. Carrying over 100 types of security products, its distribution rights for some of its products span 10 countries in Asia Pacific, including Singapore, Brunei, Vietnam, Indonesia, Malaysia, Thailand, China (Hong Kong and Macau), Australia, India and Sri Lanka.
Over the years, IPS Securex has received several sales, business and branding awards and built an accomplished reputation in the security products and solutions industry. Some of its awards include the Enterprise 50 Award in 2009, the Singapore SME 500 Company Award in 2010, the Top 100 Singapore Excellence Award (Platinum) in 2013 and the Asia Pacific Brands Award in 2014.
IPS Securex Holdings Limited has received a letter of appointment from Bio-Nexus Ltd as a subcontractor for the deployment and maintenance of Bio-Nexus’ Care-Nexus software system at the Visy Group’s Chicago site as well as at 15 additional sites of the Visy Group.
IPS Securex Holdings Limited today announced that it has entered into a memorandum of understanding relating to the proposed acquisition of equity interests in Yatai Security & Communications Pte. Ltd. and Avac Systems Pte. Ltd. (collectively, the “Target Companies”).
IPS Securex Holdings Limited announced that it has been notified by IPS Technologies Pte. Ltd., the Company’s controlling shareholder, that it will be completing the sale of 8,900,000 ordinary shares in the Company, representing approximately 5.50% of the issued share capital of the Company to certain institutional investors at the price of S$0.71 per Share or for an aggregate consideration of S$6,319,000.